# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-25-059297
Filing Date
2025-04-28
Accepted
2025-04-28 16:09:05
Documents
19
Period of Report
2025-04-28

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | achv-20250424.htm iXBRL | DEF 14A | 1695640
2 | GRAPHIC | img228350020_0.jpg | GRAPHIC | 4189
3 | GRAPHIC | img228350020_1.jpg | GRAPHIC | 573275
4 | GRAPHIC | img228350020_2.jpg | GRAPHIC | 573091
5 | GRAPHIC | img228350020_3.jpg | GRAPHIC | 4189
6 | GRAPHIC | img228350020_4.jpg | GRAPHIC | 934395
7 | GRAPHIC | img228350020_5.jpg | GRAPHIC | 691556
| Complete submission text file | 0000950170-25-059297.txt |  | 9357062

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
8 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | achv-20250424.xsd | EX-101.SCH | 13821
21 | EXTRACTED XBRL INSTANCE DOCUMENT | achv-20250424_htm.xml | XML | 475833

Mailing Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021
Business Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021 425-686-1500
ACHIEVE LIFE SCIENCES, INC. (Filer) CIK: 0000949858 (see all company filings)

EIN.: 954343413 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 033-80623 | Film No.: 25880382
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)